Behind the Paper

The real stories behind the latest research papers, from conception to publication, the highs and the lows

USP43 promotes gemcitabine resistance in bladder cancer by stabilizing E2F1 to regulate cholesterol homeostasis

Gemcitabine (GEM) resistance remains a critical barrier in the treatment of bladder cancer (BLCA). Based on the observation that metabolic reprogramming drives chemoresistance, we identified USP43 as a promoter of GEM resistance via an E2F1-driven mechanism that modulates cholesterol metabolism.
Go to the profile of Lingao Ju +4
Lingao Ju and 4 others
Jan 07, 2026